Crimes Against Humanity: Entry 1, Articles 1 & 2
Bringing forth the full Moonshine catalog of COVID-19 articles drawing back to early February 2020 from the first article to the last
INTRODUCTION
If you are new or unfamiliar with Political Moonshine, please take a moment to read this brief but important introduction to the work and the author. It provides imperative background context to the full COVID-19 catalog exceeding 315 articles.
ARTICLES 1 & 2:
The impetus for the first COVID-19 article was a simple and singular point: I wanted to know more about Remdesivir and the company behind it, Gilead Sciences.
I never intended to go beyond that inquiry and certainly never expected to dedicate going on three years of pro bono work compiling the most exclusive, comprehensive and authoritative catalog of work providing the most reliable and accurate explanation of the truth about COVID-19 to be found anywhere.
Moonshine has been ahead of the MSM by about two years. Consider that on 05 Jun 21, the New York Post wrote a so-called “exclusive” article on Anthony Fauci and COVID-19 that was essentially a complete recapitulation of my first two articles.
ARTICLE 1 / 09 Feb 20:
PECULIAR BACKSTORY TO CORPORATION BEHIND CORONAVIRUS TREATMENT POINTS TO GEORGE SOROS
A breaking story today from The Gateway Pundit spurred some additional research that produced interesting findings.
First, according to TGP, “Dr. George Diaz, a section chief for infectious diseases at Providence Regional Medical Center Everett joined Arthel Neville on FOX News on Sunday morning to discuss the successful treatment of the center’s coronavirus patient.” (SOURCE)
Important in this story is the drug that was provided in the successful treatment – Remdesivir. The antiviral drug Remdesivir was developed by GILEAD SCIENCES, which is headquartered in Foster City, CA.
Interestingly, Gilead Sciences goes back to a previous battle with Hillary Clinton over pharmaceutical company regulation. It was a fight that impacted Gilead and other big pharma corporations financially. See HERE and HERE for example.
Also relevant in all of this are questions about the origins of coronavirus and whether it’s a natural occurrence or perhaps a manufactured one. See HERE and HERE for example. At least one Canadian scientist working on the origins of Coronavirus in the capacity of biological warfare and other applications is already dead under suspicious circumstances. See HERE.
Now consider how virus outbreaks impact countries and corporations in opposite fashions. They can bankrupt nations given the magnitude of the outbreak and the requisite level of response. See HERE, HERE, and HERE.
But what about corporations? Well, that all depends on the corporation. Here are some interesting facts about Gilead Sciences – the corporation that developed Remdesivir:
Gilead supported a blend of candidates in 2016, whom were likely situated so as to act favorably toward Gilead legislatively. SOURCE
Gilead curiously supported Clinton despite her public war against pharmaceutical companies. SOURCE
Gilead was intricately involved in a drug purchasing group called UNITAID and its stated purpose was to create a patent pool for pharmaceutical companies to share their drug patents with other companies to produce generic versions for widespread distribution in selected African nations. Sales of the generic meds then generate royalties payable to the patent holders. SOURCE
Who is the billionaire investor behind Unitaid? It’s none other than George Soros.
Unitaid was supported by Democrat lawmaker Henry Waxman as demonstrated in his letter to Hillary Clinton whereby he solicited support from the Obama administration. SOURCE
Interestingly and standing counter to known Unitaid objectives, Unitaid’s board voted in 2009 to EXCLUDE CHINA among other nations; including Brazil, when considering targeted nations outside of Africa. It could be that the board caved toward industry pressure as China and Brazil are seen as preferred marketplaces. SOURCE
Unitaid’s current information on China is HERE.
THIS is more information on the Unitaid patent pool.
Now consider this quote that is derived from THIS Unitaid report dated 05-06 Dec 18 (emphasis mine.)
THE REPRESENTATIVE OF WHO informed the Board of a recent meeting coordinated by WHO with several global health partners (GPEI, GFF, Gavi, Unitaid, Global Fund) to support the development of a common health narrative. With regard to parliamentary engagement, he informed of a new Memorandum of Understanding (MoU) between WHO and the Inter-parliamentary Union and encouraged Unitaid to build on this commitment in its country work. He underlined the important role of Board members in supporting the Unitaid Secretariat by opening new doors and leveraging existing political and other connections. He also gave positive feedback on the recent Unitaid-WHO visit to China, which explored opportunities for engagement.
Unitaid – Minutes of the 30th Executive Board (EB30) (5-6 December 2018) Marrakesh, Morocco
Given the out-of-nowhere outbreak of the coronavirus and its highly suspicious genesis, it’s important to ask, “Cui bono?”
This then becomes the relevant question. If Unitaid couldn’t go to China as they wished, might they be permitted to do so if a legitimate cause presented itself and if so, who would benefit?
Now ask yourself if the outbreak of Cornoavirus in China and its global implications just might be sufficient enough to justify patent pools globally and especially in China? Is coronavirus the vehicle for George Soros to get into China with Unitaid and Gilead and clean-up?
Sure looks like it.
-End-
ARTICLE 2 / 09 Feb 20:
MORE ON GILEAD SCIENCES – THE CORPORATION BEHIND THE TREATMENT FOR CORONAVIRUS
The Convergence of circumstances and facts is awfully difficult to ignore. For an introduction to why GILEAD SCIENCES is relevant to the Cornoavirus scenario, see THIS article which established a direct line from Coronavirus to George Soros.
So here we are. We have a viral epidemic originating in China and with legitimate – very legitimate – arguments about whether this coronavirus is a natural occurrence or some leaked biological weapon. One Canadian biological warfare researcher of this precise specialty is already dead, evidence suggests 4 separate HIV insertions indicative or suggestive of the virus being bio-engineering, the CDC claims to be in the dark because China refuses to cooperate and all of it ties back to a nefarious oligarch whose tentacles reach far and deep into everything wrong, evil and corrupt – George Soros.
So, let’s take a look a closer look at Gilead Sciences, the developer of the drug Remdesivir. It’s veneer level stuff with deeper digging needed but let’s see what can we learn (SOURCE).
Over the years, the company has specialized in the research and development of both anti-cancer and anti-viral treatments. It transitioned out of anti-cancer assets in 2002.
Donald Rumsfeld was recruited to the board in 1988 and the company envelops a number of politicians and governmental figures from both sides of the aisle and with deep Harvard roots.
Gilead debuted on the NASDAQ in January of 1992 and to the tune of $86.26 billion.
Rumsfeld was appointed chairman in 1997 before leaving to become Secretary of Defense in 2001.
By 2017, Gilead’s strong history of growth, performance and acquisitions had lost some of its luster and they needed new products to maintain profitability. Consider, “As of 2017, Gilead’s challenge is to develop or acquire new blockbuster drugs before its current revenue-producers wane or their patent protection expires.”
Notice how the need ties directly to patents as outlined in the first article, which specifically pertained to patent pools? That’s important to remember when considering problem/solution scenarios.
Gilead’s struggles were enmeshed in pricing controversies and ultimately tied to poor management that also funneled money into their own pockets, “To begin with, the evidence that Gilead itself uses its profits to “innovate” is thin at best. In 2016, the company reported profit of $13.5 billion. It spent $11 billion to repurchase its own shares, and about $2.5 billion on stock dividends. So the buybacks and dividends together came to $13.5 billion, in effect consuming 100% of the company’s profit.” (SOURCE)
Oddly, Soros dumped his entire position in Gilead in the second quarter of 2014. (SOURCE)
He did the same in the second quarter of 2016 and right before shares eventually rose by 45%. (SOURCE)
Here’s where that leaves us.
We have a company in Gilead that intimately ties back to Harvard and the federal government and which specializes in anti-cancer and anti-viral medications; especially HIV. It also ties directly to biological weapons. Moreover, the company is losing patent protections while it simultaneously engaging in patent pools. It’s also working to develop new products while illegally fixing the prices of its current ones; while also lining their own pockets illegitimately. At the same time we also have Unitaid, funded by billionaire investor George Soros, working to expand Gilead’s patent pool operations in China, which just so happens to be experiencing a viral outbreak with 4 anomalous HIV insertions. An outbreak in China whereby a Washington State doctor just used Gilead’s drug Remdesivir to demonstrate the first likely effective treatment. All of this against the backdrop of Soros moving out of his entire Gilead position more than once.
Does the federal government benefit from seeing China impacted economically and domestically from such a viral outbreak? Yes. Is the federal government tied to Gilead? Yes. Does Gilead have the capacity to plausibly bio-engineer the coronoavirus with HIV insertions? Yes. Does Gilead benefit from an outbreak in China? Yes. Does Soros have a history of manipulating his holdings with Gilead? Yes. Does Unitaid, which partners with Gilead in patent pooling, stand to benefit from a coronavirus epidemic in China? Yes. Could Soros-backed Unitaid be the conduit to for Gilead to open patent pooling for coronavirus ergo kick-starting Gilead back to financial success and all at the expense of China? Yes. That is a logical argument.
Is that all speculation? Yes. But its speculation rooted in a convergence of fact sets that are difficult to ignore. That said, it’s still speculation and speculation that is veneer level. Proving something like that is a different endeavor.
Or it all just happened by chance.
-End-